hit counter
Adaptimmune Therapeutics plc (ADAP) Stock News Sentiment & Price - Sentifly
ADAP - Sentifly



Your watchlist is empty. Go add some tickers to it!

Adaptimmune Therapeutics plc (ADAP)

United Kingdom
ADAP Price and Sentiment
Positive, Negative
Loading chart...
ADAP Latest news
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
2021-10-21 08:00

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ended September 30, 2021, before the US markets open on Thursday, November 4, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) that same day (details below).

The Motley Fool
2 Top Healthcare Stocks That Could Be Bought Out in 2022
2021-10-16 07:00

These two novel-drug makers could be top takeover targets next year.

Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
2021-10-05 08:00

- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS -

Seeking Alpha
Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
2021-09-29 10:18

Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval.

The Motley Fool
3 Biotech Stocks That Could Make You Filthy Rich
2021-09-27 10:08

These three low-priced cancer stocks could be grossly undervalued.

Zacks Investment Research
Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions?
2021-09-24 09:59

Adaptimmune (ADAP) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

The Motley Fool
Why Adaptimmune Therapeutics Was Sinking This Week
2021-09-17 16:48

Profit-taking seemed to be the general dynamic behind the biotech's 14% slide.

Adaptimmune Shares Encouraging Data From Solid Tumor Trial
2021-09-13 09:50

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced updated data from its Phase 1 SURPASS trial in multiple solid tumors evaluating ADP-A2M4CD8. ADP-A2M4CD8 is a next-generation T-cell therapy engineered to target MAGE-A4 positive tumors and to express a CD8? co-receptor.

ADAP Stock: Why It Increased Today
2021-09-13 08:02

The stock price of Adaptimmune Therapeutics PLC (NASDAQ: ADAP) increased by over 10% pre-market today. This is why it happened.

Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
2021-09-13 07:00

- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers -

Loading more news...